Department of Retina, Giridhar Eye Institute, Kochi, Kerala, India.
Department of Retina, Little Flower Hospital and Research Centre, Angamaly, Kerala, India.
Middle East Afr J Ophthalmol. 2024 Sep 13;30(3):136-140. doi: 10.4103/meajo.meajo_15_24. eCollection 2023 Jul-Sep.
The purpose of this study was to analyze the incidence of retinopathy of prematurity (ROP), treatment requiring ROP (TROP), course, and systemic risk factors in extreme preterm or extreme low-birth-weight babies.
A retrospective analysis of neonatal intensive care unit-based ROP screening from January to December 2021 in a tier-2 city in Kerala, India, was done. Inclusion criteria were gestational age (GA) ≤28 weeks or birth weight ≤1000 g. ROP screening and treatment were done according to the International Classification of ROP guidelines. Treatment was indicated in babies with type 1 ROP or aggressive ROP. Details of ROP screening, treatment, and neonatal risk factors were collected from the records. The results were statistically analyzed, and < 0.05 was considered statistically significant.
The study included 54 babies with a mean GA of 27.47 ± 1.76 weeks and a mean BW of 847.43 ± 189.22 g. ROP was detected at an average postmenstrual age of 33.8 ± 1.7 weeks. The incidence of any ROP and TROP was 87% and 19.14%, respectively. All babies with TROP were managed with laser or intravitreal antivascular endothelial growth factor injection or both. ROP resolved spontaneously in 60%, but those with Zone 2 disease had delayed regression. Inotropic support and anemia were found to increase the risk for ROP.
The incidence and outcome of any ROP and TROP in this study are comparable to the rates reported globally, and this reflects the improvement in neonatal care. The use of inotropes and anemia may increase the risk for ROP and needs to be managed judiciously.
本研究旨在分析极早产儿或极低出生体重儿中早产儿视网膜病变(ROP)的发生率、需要治疗的 ROP(TROP)、病程和全身危险因素。
对印度喀拉拉邦一个二级城市新生儿重症监护病房 2021 年 1 月至 12 月进行的 ROP 筛查进行回顾性分析。纳入标准为胎龄(GA)≤28 周或出生体重≤1000 g。ROP 筛查和治疗均按照国际 ROP 分类指南进行。对 1 型 ROP 或侵袭性 ROP 患儿进行治疗。从记录中收集 ROP 筛查、治疗和新生儿危险因素的详细信息。对结果进行统计学分析,<0.05 为统计学显著。
该研究纳入了 54 名患儿,平均 GA 为 27.47 ± 1.76 周,平均 BW 为 847.43 ± 189.22 g。ROP 平均在矫正月龄 33.8 ± 1.7 周被发现。任何 ROP 和 TROP 的发生率分别为 87%和 19.14%。所有 TROP 患儿均接受激光或玻璃体内抗血管内皮生长因子注射或两者联合治疗。ROP 自发消退率为 60%,但 Zone 2 病变消退延迟。发现正性肌力支持和贫血会增加 ROP 的风险。
本研究中任何 ROP 和 TROP 的发生率和结局与全球报道的比率相当,这反映了新生儿护理的改善。正性肌力支持和贫血的使用可能会增加 ROP 的风险,需要谨慎管理。